A 2026 dermatology review describes the hair loss reported on GLP-1 medicines as most likely this kind of shedding, caused by the metabolic stress of losing weight rather than by the drug acting on hair follicles. In the Zepbound trials, hair loss was reported by 7.1% of women and 0.5% of men, against 1.3% and 0% on placebo.1,2
What it is
The review defines the pattern as "diffuse hair shedding after 2–3 months of a triggering event".1 The delay is what makes it recognizable: hair that falls today was set off by something that happened months earlier. The follicles are not destroyed in this kind of shedding, which is why the hair grows back once the trigger has passed and weight is stable.1
A study of 140 people with shedding after weight loss, none of them on these drugs, found the same pattern after losing a similar share of weight by other means. Shedding began anywhere from right away to 6 months after the weight loss, and recovery took 4.8 months on average, from two weeks to 16 months.3
What the labels report
| Medicine | Women, drug | Women, placebo | Men, drug | Men, placebo |
|---|---|---|---|---|
| Zepbound, all doses | 7.1% | 1.3% | 0.5% | 0% |
| Wegovy 2.4 mg | 4% | 2% | 0.9% | 0% |
| Wegovy 7.2 mg | 8.4% | 1.5% | 0.2% | 0% |
Both labels say hair loss "was associated with weight reduction". Two findings fit that reading. By dose, Zepbound shows no trend: 5, 4 and 5 in 100 people on 5, 10 and 15 mg. And on Wegovy, the 7.2 mg dose, which took off more weight, 18.8% against 15.5% on 2.4 mg, came with more hair loss, 5.8% against 3.3%.2,4
Not all hair loss is the same
A 2026 meta-analysis pooled 17 studies of GLP-1 drugs and hair loss and estimated the odds by type at 12 months, compared with people not on these drugs. Telogen effluvium came out 1.76 times as likely, and androgenetic alopecia, gradual pattern thinning, 1.64 times. Alopecia areata, the patchy autoimmune kind, showed no clear difference.5 Pattern thinning is different from shedding: it does not reverse on its own, and telling the two apart is the main reason to see a dermatologist when shedding does not settle.1
What to expect
The 2026 review calls the shedding usually self-limited, with regrowth expected within 3 to 6 months once weight is stable. It advises seeing a dermatologist if the diagnosis is unclear, if scarring hair loss is suspected, or if there is no improvement after 3 to 6 months.1 Because weight falls fastest in the first 24 weeks on tirzepatide and keeps falling more slowly until it levels off, the window in which shedding can start is long.6
The review's other steps are practical. It advises enough protein and correcting any micronutrient deficiencies, and links this kind of shedding to low ferritin, low vitamin D and abnormal thyroid tests. It suggests considering a slower dose climb or steadier weight loss, and it says stopping the drug is not required unless the hair loss is severe, persistent or very distressing.1 Nutrition matters in another way too. A 2025 advisory from four medical societies lists excessive hair loss among the signs of a real nutrient deficiency during GLP-1 treatment, next to unusual fatigue, muscle weakness and poor wound healing.7 Our pages on protein on a GLP-1 and on hair loss on Zepbound go further.
Sources
- Seyed Jafari SM, Caro G, Lipner SR, Iorizzo M. The impact of GLP-1 receptor agonists on hair: beneficial effects or adverse outcomes? Am J Clin Dermatol 2026;27:579-586. doi:10.1007/s40257-026-01021-6
- ZEPBOUND (tirzepatide) prescribing information, NDA 217806/S-041, revised August 2026. U.S. Food and Drug Administration; sections 2.1 and 6.1. accessdata.fda.gov
- Kang DH, Kwon SH, Sim WY, Lew BL. Telogen effluvium associated with weight loss: a single center retrospective study. Ann Dermatol 2024;36:384-388. doi:10.5021/ad.24.043
- WEGOVY (semaglutide) prescribing information, NDA 215256/S-025, revised June 2026. U.S. Food and Drug Administration; section 6.1. accessdata.fda.gov
- Viquez Burboa GU, Flores Guillén MÁR, Duardo González VS. GLP-1 receptor agonists and alopecia: a systematic review and meta-analysis of incidence, risk, subtypes, and mechanisms. Skin Appendage Disord 2026. doi:10.1159/000553070
- Horn DB, Kahan S, Batterham RL, et al. Time to weight plateau with tirzepatide treatment in the SURMOUNT-1 and SURMOUNT-4 clinical trials. Clin Obes 2025;15:e12734. doi:10.1111/cob.12734
- Mozaffarian D, Agarwal M, Aggarwal M, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Obesity (Silver Spring) 2025;33:1475-1503. doi:10.1002/oby.24336
Related analyses
Zepbound hair loss: how common it is, when it starts, and whether it grows back
How much protein to eat on Zepbound or Wegovy: the targets, calculated for your weight
What to eat on a GLP-1: the priorities of four medical societies, with a day you can build
Zepbound plateau: when weight loss slows, why, and what the trials show
Log your weight weekly and see when the fast phase ends, the usual trigger for shedding.
Open Dose Insider